- Home
- RARE vs CDP Comparison
RARE vs CDP Comparison
Compare RARE & CDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- CDP
- Stock Information
- Founded
- RARE 2010
- CDP 1988
- Country
- RARE United States
- CDP United States
- Employees
- RARE N/A
- CDP N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- CDP Real Estate Investment Trusts
- Sector
- RARE Health Care
- CDP Real Estate
- Exchange
- RARE Nasdaq
- CDP Nasdaq
- Market Cap
- RARE 3.3B
- CDP 3.0B
- IPO Year
- RARE 2014
- CDP N/A
- Fundamental
- Price
- RARE $37.17
- CDP $28.12
- Analyst Decision
- RARE Strong Buy
- CDP Buy
- Analyst Count
- RARE 17
- CDP 6
- Target Price
- RARE $92.29
- CDP $33.50
- AVG Volume (30 Days)
- RARE 974.0K
- CDP 893.4K
- Earning Date
- RARE 07-31-2025
- CDP 07-28-2025
- Dividend Yield
- RARE N/A
- CDP 4.34%
- EPS Growth
- RARE N/A
- CDP N/A
- EPS
- RARE N/A
- CDP 1.24
- Revenue
- RARE $590,689,000.00
- CDP $748,556,000.00
- Revenue This Year
- RARE $18.94
- CDP N/A
- Revenue Next Year
- RARE $28.93
- CDP $5.84
- P/E Ratio
- RARE N/A
- CDP $22.59
- Revenue Growth
- RARE 33.46
- CDP 5.34
- 52 Week Low
- RARE $29.59
- CDP $23.84
- 52 Week High
- RARE $60.37
- CDP $34.22
- Technical
- Relative Strength Index (RSI)
- RARE 55.64
- CDP 63.60
- Support Level
- RARE $35.73
- CDP $27.17
- Resistance Level
- RARE $36.22
- CDP $27.87
- Average True Range (ATR)
- RARE 1.37
- CDP 0.43
- MACD
- RARE 0.25
- CDP 0.04
- Stochastic Oscillator
- RARE 90.54
- CDP 95.45
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About CDP COPT Defense Properties of Beneficial Interest
COPT Defense Properties is a real estate investment trust that acquires, manages, and leases office and data center properties throughout the U.S. The majority of the company's real estate portfolio is composed of office buildings in the Baltimore-Washington Corridor and Northern Virginia area. COPT derives nearly all of its income in the form of rental revenue from tenants. Most of the company's revenue comes from the leasing of properties to U.S. Government agencies and its contractors in the national security, defense, and IT sectors, such as Northrop Grumman and Boeing. Regional offices in urban submarkets make also make up a sizable percentage of COPT's total square footage.